Evidence map›Paper›PMID 29126391›Full record

ArticleBMC cancer2017

MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1.

Priscila Daniele Ramos Cirilo, Luciana Nogueira de Sousa Andrade, Bruna Renata Silva Corrêa, Mei Qiao, Tatiane Katsue Furuya, Roger Chammas, Luiz Otavio Ferraz Penalva

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. MiRNA-224-5p regulates the defective permeability barrier in sensitive skin by targeting claudin-5.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Prohibitin 1 in liver injury and cancer.Experimental biology and medicine (Maywood, N.J.) · 2020
    Review
  12. Review
  13. Article
  14. Article
  15. Alkylating anticancer agents and their relations to microRNAs.Cancer drug resistance (Alhambra, Calif.) · 2019
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. MicroRNA-195: a review of its role in cancers.OncoTargets and therapy · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Priscila Daniele Ramos CiriloInstituto do Câncer do Estado de São Paulo, Centro de Investigação Translacional em Oncologia, Laboratório de Oncologia Experimental, Av. Dr. Arnaldo,251, São Paulo, SP, CEP 01246-000, Brazil.
Luciana Nogueira de Sousa AndradeInstituto do Câncer do Estado de São Paulo, Centro de Investigação Translacional em Oncologia, Laboratório de Oncologia Experimental, Av. Dr. Arnaldo,251, São Paulo, SP, CEP 01246-000, Brazil.
Bruna Renata Silva CorrêaThe University of Texas Health Science Center at San Antonio, Children's Cancer Research Institute, 7703 Floyd Curl Drive, San Antonio, TX, 78229-390, USA.
Mei QiaoThe University of Texas Health Science Center at San Antonio, Children's Cancer Research Institute, 7703 Floyd Curl Drive, San Antonio, TX, 78229-390, USA.
Tatiane Katsue FuruyaInstituto do Câncer do Estado de São Paulo, Centro de Investigação Translacional em Oncologia, Laboratório de Oncologia Experimental, Av. Dr. Arnaldo,251, São Paulo, SP, CEP 01246-000, Brazil.
Roger ChammasInstituto do Câncer do Estado de São Paulo, Centro de Investigação Translacional em Oncologia, Laboratório de Oncologia Experimental, Av. Dr. Arnaldo,251, São Paulo, SP, CEP 01246-000, Brazil.
Luiz Otavio Ferraz PenalvaThe University of Texas Health Science Center at San Antonio, Children's Cancer Research Institute, 7703 Floyd Curl Drive, San Antonio, TX, 78229-390, USA. penalva@uthscsa.edu.
Instituto do Câncer do Estado de São Paulo · BRThe University of Texas Health Science Center at San Antonio · USCentro de Pesquisas Oncológicas · BR

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2013/11721-0Fundação de Amparo à Pesquisa do Estado de São Paulo 2013/25483-4
6 · The paper itself

Abstract

backgroundMelanoma is the most lethal type of skin cancer. Since chemoresistance is a significant barrier, identification of regulators affecting chemosensitivity is necessary in order to create new forms of intervention. Prohibitin 1 (PHB1) can act as anti-apoptotic or tumor suppressor molecule, depending on its subcellular localization. Our recent data shown that accumulation of PHB1 protects melanoma cells from chemotherapy-induced cell death. Lacking of post-transcriptional regulation of PHB1 could explain this accumulation. Interestingly, most of melanoma patients have down-regulation of microRNA-195. Here, we investigate the role of miR-195, its impact on PHB1 expression, and on chemosensitivity in melanoma cells.

methodsTCGA-RNAseq data obtained from 341 melanoma patient samples as well as a panel of melanoma cell lines were used in an expression correlation analysis between PHB1 and predicted miRNAs. miR-195 impact on PHB1 mRNA and protein levels and relevance of this regulation were investigated in UACC-62 and SK-MEL-5 melanoma lines by RT-qPCR and western blot, luciferase reporter and genetic rescue experiments. Cell proliferation, cell-cycle analysis and caspase 3/7 assay were performed to investigate the potential action of miR-195 as chemosensitizer in melanoma cells treated with cisplatin and temozolomide.

resultsAnalysis of the TCGA-RNAseq revealed a significant negative correlation (Pearson) between miR-195 and PHB1 expression. Moreover, RT-qPCR data showed that miR-195 is down-regulated while PHB1 is up-regulated in a collection of melanoma cells. We demonstrated that miR-195 regulates PHB1 directly by RT-qPCR and western blot in melanoma cells and luciferase assays. To establish PHB1 as a relevant target of miR-195, we conducted rescue experiments in which we showed that PHB1 transgenic expression could antagonize the suppressive effect miR-195 on the proliferation of melanoma cells. Finally, transfection experiments combined with drug treatments performed in the UACC-62 and SK-MEL-5 melanoma cells corroborated miR-195 as potential anti-proliferative agent, with potential impact in sensitization of melanoma cell death.

conclusionsThis study support the role of miR-195 as anti-proliferative miRNA via targeting of PHB1 in melanoma cells.

Indexed as

ApoptosisCell Line, TumorCell MovementCell ProliferationCisplatinDacarbazineDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansIndolesMaleMelanomaMicroRNAsProhibitinsRepressor ProteinsCisplatinDacarbazineIndolesMicroRNAsMIRN195 microRNA, humanPHB protein, humanProhibitinsRepressor ProteinsSulfonamidesTemozolomideVemurafenibCisplatinMelanomamicroRNA-195Prohibitin 1TemozolomideVemurafenib

Identifiers

PMID29126391
PMCPMC5681823
OpenAlexW2767647932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.